Anika Therapeutics (ANIK) Tops Q4 EPS by 45c ;Offers Guidance
Get Alerts ANIK Hot Sheet
Price: $20.51 +0.34%
EPS Growth %: +950.0%
Financial Fact:
Comprehensive income (loss): 9.26M
Today's EPS Names:
OMID, BCML, CZNC, More
EPS Growth %: +950.0%
Financial Fact:
Comprehensive income (loss): 9.26M
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q4 EPS of $0.31, $0.45 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $30.6 million versus the consensus estimate of $29.1 million.
GUIDANCE:
Anika Therapeutics sees FY2026 revenue of $114-122.5 million, versus the consensus of $116.4 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US Treasury: 'Authorizing Wind Down Activities...the Offloading of Cargo Involving Certain Persons or Vessels Blocked on October 21, 2026'
- Electronic Arts announces restructuring
- Cleveland-Cliffs (CLF) PT Raised to $18 at B.Riley
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share